• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.对来自五大洲的革兰阳性临床病原体进行的替拉万星活性的全球评估和更新（2010 年）。
Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. doi: 10.1128/AAC.00011-12. Epub 2012 Apr 16.
2
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.替加环素对从皮肤及皮肤结构感染患者中分离出的革兰氏阳性菌的活性。
J Chemother. 2010 Oct;22(5):304-11. doi: 10.1179/joc.2010.22.5.304.
3
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.替考拉宁对近期从美国各地收集的革兰氏阳性临床分离株活性的比较监测研究。
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.
4
Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.应用修订后的药敏试验方法时，针对全球革兰氏阳性临床分离株集合（2013年）进行体外测试的替拉万星活性更新情况。
Diagn Microbiol Infect Dis. 2015 Apr;81(4):275-9. doi: 10.1016/j.diagmicrobio.2014.12.011. Epub 2014 Dec 31.
5
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).替拉万星对来自全球的革兰阳性临床分离株的体外活性研究（2014 年）。
J Glob Antimicrob Resist. 2017 Sep;10:271-276. doi: 10.1016/j.jgar.2017.03.018. Epub 2017 Jul 19.
6
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.替考拉宁对革兰氏阳性病原体的抗菌谱及效力的全球概述：2007至2008年监测结果
Diagn Microbiol Infect Dis. 2010 Aug;67(4):359-68. doi: 10.1016/j.diagmicrobio.2010.03.009.
7
Antimicrobial Activity of Telavancin Tested Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017).泰利霉素针对包括多药耐药分离株在内的全球革兰阳性病原体的抗菌活性研究（2015-2017 年）。
Microb Drug Resist. 2020 Aug;26(8):934-943. doi: 10.1089/mdr.2019.0104. Epub 2020 Feb 12.
8
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).替拉万星对来自美国医院的当代革兰氏阳性病原体的活性测试 (2007-2009)。
Diagn Microbiol Infect Dis. 2012 Jan;72(1):113-7. doi: 10.1016/j.diagmicrobio.2011.09.023. Epub 2011 Nov 10.
9
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.特拉万星对来自美国69家医疗中心的临床重要革兰氏阳性病原体的体外活性（2015年）：按美国人口普查分区进行的效价分析
Microb Drug Resist. 2017 Sep;23(6):718-726. doi: 10.1089/mdr.2017.0022. Epub 2017 Jul 20.
10
Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017.2013 年至 2017 年全球临床实验室分离的革兰氏阳性菌对依拉环素的活性。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01715-19.

引用本文的文献

1
Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.由高度耐青霉素的草绿色链球菌引起的心内膜炎：万古霉素为基础的治疗方案仍有一席之地。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00516-19. Print 2019 Aug.
2
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.采用改良肉汤微量稀释法评估替拉万星对3期医院获得性肺炎/呼吸机相关性肺炎临床分离株的最低抑菌浓度
Infect Dis Ther. 2016 Dec;5(4):535-544. doi: 10.1007/s40121-016-0133-y. Epub 2016 Oct 7.
3
Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.特拉万星治疗金黄色葡萄球菌医院获得性肺炎及呼吸机相关性肺炎：临床证据与经验
Ther Adv Respir Dis. 2016 Aug;10(4):368-78. doi: 10.1177/1753465816651594. Epub 2016 Jun 23.
4
Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.医院获得性肺炎治疗的当前及未来考量
Adv Ther. 2016 Feb;33(2):151-66. doi: 10.1007/s12325-016-0293-x. Epub 2016 Feb 9.
5
Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.在肉汤微量稀释法最小抑菌浓度（MIC）及一室药代动力学/药效学模型中，替拉万星对耐甲氧西林金黄色葡萄球菌分离株显示出活性，这些分离株对万古霉素、达托霉素和利奈唑胺的敏感性降低。
Antimicrob Agents Chemother. 2015 Sep;59(9):5529-34. doi: 10.1128/AAC.00773-15. Epub 2015 Jun 29.
6
Update on the emerging role of telavancin in hospital-acquired infections.特拉万星在医院获得性感染中新兴作用的最新进展。
Ther Clin Risk Manag. 2015 Apr 13;11:605-10. doi: 10.2147/TCRM.S57376. eCollection 2015.
7
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.达托霉素对来自美国的一批耐甲氧西林金黄色葡萄球菌分离株（包括耐药亚组）的体外活性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1811-4. doi: 10.1128/AAC.04616-14. Epub 2015 Jan 5.
8
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.替考拉宁在革兰氏阳性病原体所致菌血症感染中的潜在作用：聚焦于金黄色葡萄球菌。
Clin Infect Dis. 2015 Mar 1;60(5):787-96. doi: 10.1093/cid/ciu971. Epub 2014 Dec 3.
9
Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.采用修订后的CLSI参考肉汤微量稀释法时替考拉宁的质量控制MIC范围。
J Clin Microbiol. 2014 Sep;52(9):3399-401. doi: 10.1128/JCM.01210-14. Epub 2014 Jun 11.
10
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.用于治疗婴儿、儿童和成人耐甲氧西林金黄色葡萄球菌感染的近期批准药物的药代动力学和安全性。
Expert Rev Clin Pharmacol. 2014 May;7(3):327-40. doi: 10.1586/17512433.2014.909281. Epub 2014 Apr 9.

本文引用的文献

1
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).欧洲葡萄球菌临床分离株检测的替考拉宁活性更新（2009-2010 年）。
Diagn Microbiol Infect Dis. 2011 Sep;71(1):93-7. doi: 10.1016/j.diagmicrobio.2011.05.012.
2
Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.抗革兰阳性菌药物对耐甲氧西林金黄色葡萄球菌的临床活性。
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21. doi: 10.1093/jac/dkr073.
3
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.加拿大医院分离的金黄色葡萄球菌和链球菌的体外活性：2007-2009 年 CANWARD 研究结果。
Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.
4
In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.替考拉宁和比较抗菌药物对一组遗传定义的葡萄球菌的体外活性。
Diagn Microbiol Infect Dis. 2011 Mar;69(3):275-9. doi: 10.1016/j.diagmicrobio.2010.09.017.
5
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.替考拉宁对革兰氏阳性病原体的抗菌谱及效力的全球概述：2007至2008年监测结果
Diagn Microbiol Infect Dis. 2010 Aug;67(4):359-68. doi: 10.1016/j.diagmicrobio.2010.03.009.
6
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.替考拉宁对当代全球范围内金黄色葡萄球菌分离株的体外活性研究。
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
7
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.通过最低抑菌浓度（MIC）和耐药性选择研究测定替拉万星对葡萄球菌和肠球菌的活性。
Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.
8
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.特拉万星通过与细胞壁前体脂II的靶向相互作用破坏细菌膜的功能完整性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
9
In vitro activity of telavancin against resistant gram-positive bacteria.替考拉宁对耐药革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52. doi: 10.1128/AAC.01398-07. Epub 2008 Apr 28.
10
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.替考拉宁对近期从美国各地收集的革兰氏阳性临床分离株活性的比较监测研究。
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.

对来自五大洲的革兰阳性临床病原体进行的替拉万星活性的全球评估和更新（2010 年）。

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

机构信息

JMI Laboratories, North Liberty, Iowa, USA.

出版信息

Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. doi: 10.1128/AAC.00011-12. Epub 2012 Apr 16.

DOI:10.1128/AAC.00011-12
PMID:22508304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3393449/
Abstract

A total of 15,480 Gram-positive pathogens were collected from 89 sites in the United States, Europe, the Asia-Pacific region, and Latin America in 2010. Telavancin was active against indicated Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), vancomycin-susceptible Enterococcus faecalis (MIC(50/90), 0.5/0.5 μg/ml), and beta-hemolytic (MIC(50/90), 0.06/0.12 μg/ml) and viridans group streptococcus (MIC(50/90), 0.03/0.06 μg/ml) isolates. These MIC results showed potency for telavancin equal to or greater than that of comparators. These in vitro data confirm a continued potent activity of telavancin when tested against contemporary Gram-positive clinical isolates.

摘要

2010 年，从美国、欧洲、亚太地区和拉丁美洲的 89 个地点共采集了 15480 株革兰氏阳性病原体。替拉万星对指示性金黄色葡萄球菌（MIC（50/90），0.12/0.25μg/ml）、万古霉素敏感粪肠球菌（MIC（50/90），0.5/0.5μg/ml）和β溶血性（MIC（50/90），0.06/0.12μg/ml）和草绿色链球菌（MIC（50/90），0.03/0.06μg/ml）分离株具有活性。这些 MIC 结果表明，替拉万星的效力与对照药物相当或更强。这些体外数据证实了替拉万星在测试针对当代革兰氏阳性临床分离株时仍然具有强大的活性。